Anaphylactic reaction to ambroxol: a rare occurrence in pediatric practice
Allergologia et Immunopathologia · 01.11.2026 · 54 (6) · 39-42
DOI: 10.15586/aei.v54i6.1634 ↗Kurz gefasst
Fallbericht in der Zeitschrift Allergologia et Immunopathologia, online erschienen am 01.11.2026. Verfasst von Natalhie Acuña Ortega und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regional Center for Allergy and Clinical Immunology, Dr. José Eleuterio González University Hospital, Autonomous University of Nuevo León, Monterrey,…. Hauptthemen laut MEDLINE: Ambroxol, Anaphylaxis, Drug Hypersensitivity, Expectorants. Gefördert von: The authors received no financial support for the research, authorship, and/or publication of this article..
Abstract (Originalsprache)
Ambroxol is a commonly used mucolytic agent for respiratory tract infections; however, immediate hypersensitivity reactions are rarely reported in children. We describe a 13-year-old male with allergic rhinitis and atopic dermatitis who developed generalized urticaria, angioedema, dyspnea, and syncope shortly after receiving loratadine–ambroxol prescribed for an upper respiratory infection. Skin testing with amoxicillin, azithromycin, paracetamol, and ambroxol yielded negative results. Drug provocation testing (DPT) was subsequently performed, showing negative responses to amoxicillin, azithromycin, and paracetamol. During the ambroxol challenge (3–27 mg), the patient developed rhinorrhea, sneezing, ocular and nasal pruritus, followed by dyspnea, wheezing, bilateral eyelid angioedema, generalized urticaria, oxygen desaturation, tachycardia, and hypotension—findings consistent with grade III anaphylaxis according to the Brown classification. He required two intramuscular doses of epinephrine, with complete clinical recovery. Ambroxol was permanently contraindicated, and an epinephrine autoinjector was prescribed. This case reinforces that severe ambroxol-induced hypersensitivity can occur despite negative skin testing, highlighting the value of DPT. Given the widespread use of ambroxol and its potential to trigger life-threatening reactions, clinicians should prioritize rational prescribing in upper respiratory infections and report severe adverse events to pharmacovigilance systems. This case adds to the limited pediatric evidence confirming ambroxol-induced anaphylaxis through controlled drug exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Center for Allergy and Clinical Immunology, Dr. José Eleuterio González University Hospital, Autonomous University of Nuevo León, Monterrey, Mexico. Francisco I. Madero Pte., s/n, and Gonzalitos Avenue, Colonia…
Förderung
- The authors received no financial support for the research, authorship, and/or publication of this article.
Zitieren
APA
Ortega, N. A., González Díaz, S. N., Guzmán Avilán, R. I., Villalobos Ordaz, M. I., Chávez Ruiz, A. K., & Ríos González, D. S. (2026). Anaphylactic reaction to ambroxol: a rare occurrence in pediatric practice. Allergologia et Immunopathologia, 54(6), 39-42. https://doi.org/10.15586/aei.v54i6.1634
Vancouver
Ortega NA, González Díaz SN, Guzmán Avilán RI, Villalobos Ordaz MI, Chávez Ruiz AK, Ríos González DS. Anaphylactic reaction to ambroxol: a rare occurrence in pediatric practice. Allergologia et Immunopathologia. 2026;54(6):39-42. doi:10.15586/aei.v54i6.1634
BibTeX
@article{Ortega2026,
author = {Ortega, Natalhie Acuña and González Díaz, Sandra N and Guzmán Avilán, Rosa I and Villalobos Ordaz, Marcela I and Chávez Ruiz, Ana K and Ríos González, Danna S},
title = {Anaphylactic reaction to ambroxol: a rare occurrence in pediatric practice},
journal = {Allergologia et Immunopathologia},
year = {2026},
volume = {54},
number = {6},
pages = {39--42},
doi = {10.15586/aei.v54i6.1634}
}
EUVIMED